EUVIMEDEUVIMED entdecken
Crossref

Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer

Xiaoming Chen, Xia Ding, Jiebin Fang iD, Churu Mao, Xingzhi Gong, Yuxiao Zhang, Ningjing Zhang, Feihang Yan, Yijie Lou, Zhe Chen, Wanjing Ding, Zhongjun Ma iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xiaoming Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Histone Deacetylase Inhibitors, Antineoplastic Agents, Histone Deacetylases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hainan Provincial Joint Project of Sanya Yazhou Bay Science and Technology City, Public Welfare Technology Applied Research Planning Project of Zhoushan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HDAC8 is a therapeutic target with great promise for breast cancer. Here, we reported a novel compound corallorazine D from Nocardiopsis sp. XZB108, selectively inhibited HDAC8 (IC50 = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. Upon additional modifications of corallorazine D, a candidate compound 5k, demonstrated remarkable inhibitory potency against HDAC8 (IC50 = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. The selectivity of 5k was at least 439-fold, superior to corallorazine D, confirming the efficacy of our modifications. In an orthotopic mouse model of breast cancer, 5k displayed nearly 4-fold superior antitumor activity than SAHA. Furthermore, 5k triggered antitumor immunity by activating T cells. Treatment with 5k significantly increased the proportion of M1 macrophages and decreased the proportion of M2 macrophages (M1/M2 ratio = 2.67 ± 0.25). 5k represents a promising compound for further investigation as a potential treatment for breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHistone Deacetylase InhibitorsAntineoplastic AgentsHistone DeacetylasesAnimalsFemaleHumansMiceCell Line, TumorRepressor ProteinsStructure-Activity RelationshipMice, Inbred BALB CCell ProliferationXenograft Model Antitumor Assays

Substanzen

Histone Deacetylase InhibitorsHDAC8 protein, humanAntineoplastic AgentsHistone DeacetylasesRepressor Proteins

Autor:innen und Institutionen

  • Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
  • Key Laboratory of Digestive Pathophysiology of Zhejiang Province, the First Affiliated Hospital of Zhejiang Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
  • Hainan Institute of Zhejiang University, Sanya 572025, China.

ORCID-Profile: Jiebin Fang, Zhongjun Ma

Förderung

  • National Natural Science Foundation of China
  • Hainan Provincial Joint Project of Sanya Yazhou Bay Science and Technology City
  • Public Welfare Technology Applied Research Planning Project of Zhoushan

Zitieren

APA

Chen, X., Ding, X., Fang, J., Mao, C., Gong, X., Zhang, Y., Zhang, N., Yan, F., Lou, Y., Chen, Z., Ding, W., & Ma, Z. (2024). Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01438

Vancouver

Chen X, Ding X, Fang J, Mao C, Gong X, Zhang Y, et al. Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01438

BibTeX
@article{Chen2024,
  author = {Chen, Xiaoming and Ding, Xia and Fang, Jiebin and Mao, Churu and Gong, Xingzhi and Zhang, Yuxiao and Zhang, Ningjing and Yan, Feihang and Lou, Yijie and Chen, Zhe and Ding, Wanjing and Ma, Zhongjun},
  title = {Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01438}
}
Kostenlos starten →